Cailin Conner

DocwireNews

&ldquo;Sodium&ndash;glucose cotransporter-2 inhibitors (SGLT2is) decrease serum urate levels,&rdquo; investigators of a recent study in the <a href="https://www.acpjournals.org/doi/10.7326/M23-0724" target="_blank" rel="noopener">Annals of Internal Medicine</a> wrote, &ldquo;but whether this translates into prevention of recurrent flares among patients with gout and gout-primary emergency department (ED) visits or hospitalizations is unknown.&rdquo;The goal of the study was to assess gout flares and cardiovascular events in patients with gout who begin treatment with SGLT2is versus dipeptidyl peptidase 4 inhibitors (DPP-4is), an alternative second-line medication for glucose control unrelated to serum urate levels or cardiovascular risk.The investigators employed a propensity score-matched study design using a general population database spanning from January 2014 to June 2022. The primary outcome measured was recurrent gout flare counts, ascertained through various medical records, including ED visits, hospitalizations, outpatient visits, and medication dispensing records. Secondary outcomes included myocardial infarction and stroke, with genital infection as a positive control and osteoarthritis encounters as a negative control. The data analysis employed Poisson and Cox proportional hazards regressions, and the primary analysis included 1:1 propensity score matching, with sensitivity analysis using overlap weighting.Patients who initiated treatment with SGLT2is experienced significantly fewer gout flares compared with those who started with DPP-4is (rate ratio, 0.66; 95% CI, 0.57-0.75). Moreover, SGLT2i initiators also showed a decreased risk of gout-primary ED visits and hospitalizations.Furthermore, the study demonstrated that SGLT2is may offer cardiovascular benefits to gout patients. The risk of myocardial infarction was notably lower among SGLT2i initiators (hazard ratio, 0.69; 95% CI, 0.574-0.88). While the difference in the risk of stroke was not statistically significant, the findings suggest a trend toward cardiovascular protection. However, SGLT2is were found to be associated with a higher risk of genital infections.The study provides compelling evidence that SGLT2is may hold promise as a new treatment avenue for patients with gout and comorbid type 2 diabetes. These medications not only reduce the frequency of gout flares but also exhibit potential cardiovascular benefits; however, they come with the trade-off of a higher risk of genital infections.

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Study Finds Potential Benefits of SGLT2 Inhibitors in Reducing Gout Flares, Cardiovascular Risks

Gout

 A recent study comparing SGLT2is with DPP-4is in patients with gout and type 2 diabetes found that SGLT2is reduced gout flares, gout-related ED visits, and hospitalizations.

Study Finds Potential Benefits of SGLT2 Inhibitors in Reducing Gout Flares, Cardiovascular Risks 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe